Anteris Technologies (ASX: $AVR) Q4 2023 Activities Report

Anteris Technologies Ltd (ASX: $AVR) has completed the 15-patient US FDA approved Early Feasibility Study (EFS) of DurAVRTM THV to treat severe aortic stenosis, reporting outstanding haemodynamic function and successful treatment of patients. The Company raised $41.3 million during the quarter, with a cash balance of $30.8 million at 31 December 2023.

Executive Commentary on DurAVRTM THV Performance

These haemodynamics are unparalleled. This biomimetic valve not only allows us to have this acute improvement in flow from a classic haemodynamic performance but, also, we've seen (on cardiac MRI) normalisation of laminar flow out of the aorta. It's likely to have significant implications as we think about the long-term durability of the valve, stress on the leaflets but, also, aortopathies, potentially inflammation and other things as well.

Summary of Anteris Technologies' Q4 2023 Activities

Anteris Technologies (ASX: $AVR) has successfully completed the US FDA approved Early Feasibility Study for DurAVRTM THV, demonstrating outstanding haemodynamic function and successful treatment of severe aortic stenosis patients. The Company raised $41.3 million during the quarter and had a cash balance of $30.8 million at 31 December 2023. Anteris continues to evaluate a potential dual listing of its securities on NASDAQ and ASX. The Company is set to revolutionize the structural heart market by delivering clinically superior solutions for significant unmet clinical needs.